National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits in the top decile of US sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count).
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 490 sponsored US clinical trials, 50 recruiting.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors 490 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 398 completed. 69 of these trials are in Phase 3-4 (later-stage) and 178 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 25 trials.
Top-decile sponsor footprint
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ranks in the top decile of sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
398 of 424 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
490 total, page 7 of 10
Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
NCT00073255
Vermont Diabetes Information System
NCT00109369
The Medical College of Georgia PLAY Project: Exercise Dose and Insulin Sensitivity in Obese Children
NCT00108901
Testosterone and Physical Function in HIV+ Men
NCT00260143
Substrate Cycling in Energy Metabolism
NCT00361751
Epidemiology of Gallbladder Sludge and Stones in Pregnancy
NCT00131131
Hepatitis C: Grading and Staging by MR
NCT00059397
Treatment of Cholestatic Pruritus With Sertraline
NCT00058903
Type 2 Diabetes Primary Prevention for At Risk Girls
NCT00063674
Wise Mind: Environmental Approach for Obesity Prevention
NCT00065039
Improving Body Image in Middle Schoolers
NCT00067652
Increasing Physical Activity Levels in Low-Income Women
NCT00065026
Treatment of Diabetic Nephropathy
NCT00065559
The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation
NCT00056784
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
NCT00339833
Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)
NCT00082238
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
NCT00056862
Adjuvant Nutrition for Critically Ill Trauma Patients
NCT00067132
Factors Affecting Caloric Regulation in Human Feeding
NCT00108784
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
NCT00054756
Obesity Prevention in African American School Children
NCT00061165
Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis
NCT03289520
Aggrenox Prevention of Access Stenosis
NCT00067119
Quality of Life in Pediatric Inflammatory Bowel Disease
NCT00061737
Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy
NCT00050713
Prevention of Type 2 Diabetes Mellitus in Children
NCT00073268
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
NCT00212290
Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men
NCT00470990
Breaking Down Barriers to Diabetes Self-Care
NCT00142922
Impact of Non-Commercialism Policy in Seattle Schools
NCT00063700
A Cafeteria Based Study of Weight Gain Prevention
NCT00573482
Modifying the Home Television Watching Environment
NCT00065052
Hepatitis C Antiviral Resistance in African-Americans
NCT00038974
Evaluation of Diabetes Self-Management Consultant Care
NCT00109720
Treatment of Binge Eating Disorder
NCT00041743
Trial of High-dose Urso in Primary Sclerosing Cholangitis
NCT00059202
Pre-ESRD Syndrome in High Risk African Americans
NCT00224939
Sirolimus for Focal Segmental Glomerulosclerosis
NCT00040508
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
NCT00064753
Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant
NCT00063648
Prevention of Osteoporosis in Men With Prostate Cancer
NCT00048841
Esophageal Motility and Airway Defenses Among Infants
NCT00062452
Strength Training for Obesity Prevention
NCT00030160
Treatment of Binge Eating Disorder
NCT00039936
Effectiveness of Brief Counseling for Weight Management
NCT00212199
Family-Centered Diabetes Project - Sharing Wisdom
NCT00438126
Gamma Interferon Therapy for Chronic Hepatitis C
NCT00028275
Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
NCT00028093
Glucocorticoid-induced Osteopenia in Children
NCT00289328
Leptin to Treat Severe Insulin Resistance - Pilot Study
NCT00027456
What is open in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline
50 recruiting of 490 indexed (10% open); 398 completed (81%).
Phase mix: 69 late (III/IV) vs 178 early (I/II) (early-phase heavy).
Top condition: Obesity (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): open-pipeline peers nationwide
Peers matched on 490 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 490 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Mirati Therapeutics · 10% recruiting · 49 trials
- James J. Peters Veterans Affairs Medical Center · 10% recruiting · 39 trials
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
Related
What to do with this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) page
490 registered trials is a research-attention snapshot, not an endorsement of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or any single study.
- 50 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline card: 490 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.